Estimates Revisions Fennec Pharmaceuticals Inc. Deutsche Boerse AG
Stocks
RV41
CA31447P1009
Pharmaceuticals
|
Market Closed -
Deutsche Boerse AG
23:55:02 14/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 10.00 EUR | -2.91% |
|
+1.01% | +60.00% |
| 08-12 | B. Riley Adjusts Fennec Pharmaceuticals Price Target to $18 From $16, Maintains Buy Rating | MT |
| 08-11 | Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings Beat | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- FENC Stock
- RV41 Stock
- Consensus Fennec Pharmaceuticals Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
